Arundhati Parmar is VP and Editor-in-Chief at MedCity News. In this role, she oversees MedCity's news coverage as well as develops the content for several conferences that the publication hosts. Previously, she was Senior Editor at UBM's Medical Device + Diagnostic Industry. Arundhati has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again. Contact her at [email protected].
LinkedIn: https://www.linkedin.com/in/arundhati-parmar/
Twitter: @aparmarbb
Algorithms make it possible for companies to fix prices without explicitly coordinating with one another, posing a new test for regulators policing the market, said Lina Khan, chair of the Federal Trade Commission, during a media event hosted by KFF.
Two months after a cyberattack on a UnitedHealth Group subsidiary halted payments to some doctors, medical providers say they’re still grappling with the fallout, even though UnitedHealth told shareholders on Tuesday that business is largely back to normal.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medicare's Chronic Care Management program reduced emergency room and in-patient hospital visits and lowered total health spending, but uptake has been sluggish for a variety of reasons.
A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?
The recall comes years after surgeons say they first noticed problems with the HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories. The devices are not currently being removed from the market.
Ever since the Covid-19 pandemic pushed telehealth to the forefront of American healthcare modalities, the genie has emerged from the lamp to quite a mixed crowd of cheerleaders and cheaters.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Scott Davis is the CEO of Ekso Bionics, an innovative medical device company making wearable exoskeletons for use in construction but perhaps, more importantly, to help people contending with spinal cord injury.
Episode 2 of the Debunked (audio) show focuses on how hospitals are inflating prices for outpatient procedures and how California is looking at healthcare M&A and trying to address price increases and anti-competitive behavior.
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
In an interview at the Vive conference in Los Angeles, John Couris said that while he is sympathetic toward Change Healthcare's current woes, he wants definitive answers soon.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Here's the audio of Episode 1 of the newly-launched show Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare.
MedCity News is launching a new ongoing show called Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare. In this show, co-hosts Arundhati Parmar and Samir Batra will discuss healthcare news and call out things that seem utterly insane to us. The goal is to inspire change in the healthcare industry.
Anne Osdoit, CEO of Moon Surgical, explains how the Maestro System may be expanding the surgical robotics pie by bringing the capability to newer markets and how surgical robotics do not have to break the bank.
Kevin Sayer would love to bring his company's Dexcom G7 continuous glucose monitor to more people and more quickly. But despite being CEO of a successful device company, he feels frustrated from time to time about how and what the U.S. health system will pay for.
From its heady unicorn days to being newly public to its current financial struggles, the portable ultrasound-on-a-chip company has seen it all. Now, its latest CEO has his work cut out for him. A return to revenue growth is what Joseph DeVivo is promising this year.